Qyuns Therapeutics develops monoclonal antibody drugs for autoimmune diseases.
Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to tocilizumab, a Chugai drug marketed as Actemra for various rheumatoid arthritis conditions.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 7, 2022 | Series C | ¥100M | 1 | — | — | Detail |
May 7, 2020 | Series B | — | 1 | — | — | Detail |
Jul 31, 2019 | Series B | $20M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Shenzhen Kaiding Juncan venture Cci Capital | — | Series C |
Jiayin Investment | — | Series B |
Hefu Ruitai | — | Series B |